Combination locked out in ATTR-CM? ‘Dead,’ expert says
· randy osborne
AI Briefing
- • Researchers debate effectiveness of knockdown drugs and stabilizers in treating ATTR-CM.
- • Phase III trial of Wainua (eplontersen) with Astrazeneca and Ionis failed.
- • Experts consider Wainua 'dead' due to lack of synergy in treating ATTR-CM.
Source Summary
The synergy – or lack of it – between knockdown drugs and stabilizers in treating transthyretin (TTR)-mediated amyloid cardiomyopathy (ATTR-CM) became one of the topics for debate in the aftermath of the phase III fizzle with gene silencer Wainua (eplontersen), advanced by Astrazeneca plc and Ionis Pharmaceuticals Inc.
Advertisement